Investors Like the News; Stock Rockets 63%
Study Confirms Efficacy of CBLI Radiation Countermeasure
By Catherine Shaffer
Tuesday, June 5, 2012
Stock in Cleveland Biolabs Inc. surged 63 percent following the release of results from its efficacy study of radiation countermeasure product, CBLB502, showing a nearly threefold increase in overall survival among rats exposed to a 70 percent lethal dose of radiation.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.